Skip to main content
. 2019 Apr 19;10(29):2824–2834. doi: 10.18632/oncotarget.26854

Figure 3. GRM3 in U87 cells is functional.

Figure 3

Western immunoblots of U87 cells treated with specific GRM3 agonist, LY379268 (Ag, 1 μM), riluzole (RIL, (1 μM), agonist plus GRM3 specific antagonist, LY341495 (Ant, (1 μM), or Ag plus RIL. Cells were pre-incubated with antagonist or RIL for 24 and 48 hours prior to agonist challenge. The membranes were probed with pERK antibody and GAPDH antibody as loading controls.